MARKET

NBIX

NBIX

Neurocrine Biosciences Inc
NASDAQ
168.54
-1.47
-0.86%
After Hours: 169.00 +0.47 +0.28% 19:55 06/30 EDT
OPEN
170.66
PREV CLOSE
170.00
HIGH
171.50
LOW
168.24
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
171.50
52 WEEK LOW
122.14
MARKET CAP
16.95B
P/E (TTM)
25.93
1D
5D
1M
3M
1Y
5Y
1D
Neurocrine (NBIX) Receives a Buy from Jefferies
TipRanks · 16h ago
Neurocrine price target raised to $208 from $182 at UBS
TipRanks · 19h ago
Top Stock Picks for Week of June 29, 2026
NASDAQ · 1d ago
NEUROCRINE BIOSCIENCES, INC <NBIX.O>: JEFFERIES RAISES TARGET PRICE TO $200 FROM $181
Reuters · 1d ago
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day
NASDAQ · 1d ago
Weekly Report: what happened at NBIX last week (0622-0626)?
Weekly Report · 1d ago
Bull of the Day: Neurocrine Biosciences (NBIX)
NASDAQ · 1d ago
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap?
Simply Wall St · 2d ago
More
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.

Webull offers Neurocrine Biosciences, Inc stock information, including NASDAQ: NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.